ALK G1269S

CI-VAR-00001593Explore in graph →CIViC 4334

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm2
EML4::ALK Fusion AND ALK G1269S	ALK Inhibitor TAE684	Predictive	D	Supports Sensitivity Response	3	submitted	EID11077 From a mutation assay that generated crizotinib resistant mutations in EML4::ALK, the five most resistant mutations found were introduced into Ba/F3 cells and tested with the ALK inhibitor TAE684. EML… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1269S	Crizotinib	Predictive	D	Supports Resistance	4	submitted	EID11075 Ba/F3 cells with EML4::ALK were subjected to mutagen N-ethyl-N-nitrosourea and then incubated without IL3 in 250, 500, 720, 1000, 1440, or 2000 nm crizotinib. The ten most frequently seen mutants we… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.